In vitroactivity of the siderophore cephalosporin, cefiderocol, against molecularly characterized, carbapenem-non-susceptible Gram-negative bacteria from Europe

JAC-Antimicrobial Resistance - Tập 2 Số 3 - 2020
Christopher Longshaw1, Davide Manissero1, Masakatsu Tsuji2, Roger Echols3, Yoshinori Yamano4
1Infectious Diseases, Shionogi B.V., London, UK
2Marketed Product Regulatory Affairs, Shionogi & Co., Ltd., Osaka, Japan
3ID3C, LLC, Easton, CT, USA
4Pharmaceutical Research Division, Shionogi & Co. Ltd, Osaka, Japan

Tóm tắt

AbstractObjectivesMany carbapenem-resistant (CR) Gram-negative (GN) pathogens exhibit MDR, meaning few therapeutic options are available for CR-GN infections. Cefiderocol, a siderophore cephalosporin, has demonstrated in vitro efficacy against CR-GN bacteria. In the SIDERO-CR-2014–2016 surveillance study, European clinical isolates comprising carbapenem-non-susceptible (CarbNS) Enterobacterales and MDR non-fermenters were tested against cefiderocol and comparators.MethodsCefiderocol MICs were determined using iron-depleted CAMHB, and comparators using CAMHB, per recommended CLSI methodology. Carbapenemase gene profiles were determined using PCR.ResultsIsolates (N = 870) from 23 European countries comprised CarbNS Enterobacterales (n = 457), MDR Pseudomonas aeruginosa (n = 177) and MDR Acinetobacter baumannii (n = 236). The most common carbapenemases were KPC (52%), OXA-48-like (19%), VIM (14%) and NDM (8%) in Enterobacterales, VIM (41%) in P. aeruginosa and OXA-23-like (57%) and OXA-24/40-like (37%) in A. baumannii. Most carbapenemase-producing isolates (65%) co-carried ESBLs. Approximately half of P. aeruginosa isolates were negative for carbapenemases, compared with 10% of Enterobacterales and 3% of A. baumannii. A similar proportion of Enterobacterales were susceptible to cefiderocol (81.6%; 79.0% of VIM producers; 51.4% of NDM producers; based on EUCAST breakpoint values) compared with comparator antimicrobial agents, including colistin (76.4%; 93.5% of VIM producers; 78.4% of NDM producers) and ceftazidime/avibactam (76.6%; 1.6% of VIM producers; 2.7% of NDM producers). Of P. aeruginosa isolates, 98.3% were susceptible to cefiderocol (100% of VIM producers), similar to colistin (100%). Against A. baumannii, 94.9% had cefiderocol MIC ≤2 mg/L and 93.6% of isolates were susceptible to colistin.ConclusionsCefiderocol demonstrated potent activity against CarbNS and MDR GN bacteria, including non-fermenters and a wide variety of MBL- and serine-β-lactamase-producing strains.

Từ khóa


Tài liệu tham khảo

2017

2013

Morrill, 2015, Treatment options for carbapenem-resistant Enterobacteriaceae infections, Open Forum Infect Dis, 2, ofv050, 10.1093/ofid/ofv050

Bonine, 2019, Impact of delayed appropriate antibiotic therapy on patient outcomes by antibiotic resistance status from serious Gram-negative bacterial infections, Am J Med Sci, 357, 103, 10.1016/j.amjms.2018.11.009

2020

2019

Ito, 2016, In vitro antimicrobial activity of S-649266, a catechol-substituted siderophore cephalosporin, when tested against non-fermenting Gram-negative bacteria, J Antimicrob Chemother, 71, 670, 10.1093/jac/dkv402

Ito, 2016, Siderophore cephalosporin cefiderocol utilizes ferric iron transporter systems for antibacterial activity against Pseudomonas aeruginosa, Antimicrob Agents Chemother, 60, 7396, 10.1128/AAC.01405-16

Ito, 2017, In vitro antibacterial properties of cefiderocol, a novel siderophore cephalosporin, against Gram-negative bacteria, Antimicrob Agents Chemother, 62, e01454, 10.1128/AAC.01454-17

Iregui, 2020, Activity of cefiderocol against Enterobacterales, Pseudomonas aeruginosa, and Acinetobacter baumannii endemic to medical centers in New York City, Microb Drug Resist, 10.1089/mdr.2019.0298

Kohira, 2016, In vitro antimicrobial activity of a siderophore cephalosporin, S-649266, against Enterobacteriaceae clinical isolates, including carbapenem-resistant strains, Antimicrob Agents Chemother, 60, 729, 10.1128/AAC.01695-15

Ito-Horiyama, 2016, Stability of novel siderophore cephalosporin S-649266 against clinically relevant carbapenemases, Antimicrob Agents Chemother, 60, 4384, 10.1128/AAC.03098-15

Tsuji, 2015, S-649266, a novel siderophore cephalosporin: in vitro activity against Gram-negative bacteria isolated in Japan including carbapenem-resistant strains, Open Forum Infect Dis, 2, 778, 10.1093/ofid/ofv133.495

Otto, 1992, Transferrins and heme-compounds as iron sources for pathogenic bacteria, Crit Rev Microbiol, 18, 217, 10.3109/10408419209114559

Hackel, 2017, In vitro activity of the siderophore cephalosporin, cefiderocol, against a recent collection of clinically relevant Gram-negative bacilli from North America and Europe, including carbapenem-nonsusceptible isolates (SIDERO-WT-2014 Study), Antimicrob Agents Chemother, 61, e00093, 10.1128/AAC.00093-17

Tsuji, 2015

2016

2019

Hackel, 2018, In vitro activity of the siderophore cephalosporin, cefiderocol, against carbapenem-nonsusceptible and multidrug-resistant isolates of Gram-negative bacilli collected worldwide in 2014 to 2016, Antimicrob Agents Chemother, 62, e01968, 10.1128/AAC.01968-17

Kazmierczak, 2019, In vitro activity of cefiderocol, a siderophore cephalosporin, against a recent collection of clinically relevant carbapenem-non-susceptible Gram-negative bacilli, including serine carbapenemase- and metallo-β-lactamase-producing isolates (SIDERO-WT-2014 Study, Int J Antimicrob Agents, 53, 177, 10.1016/j.ijantimicag.2018.10.007

2020

Naas, 2008, Minor extended-spectrum β-lactamases, Clin Microbiol Infect, 14 Suppl 1, 42, 10.1111/j.1469-0691.2007.01861.x

Evans, 2014, OXA β-lactamases, Clin Microbiol Rev, 27, 241, 10.1128/CMR.00117-13

Lutgring, 2018, Phenotypic and genotypic characterization of Enterobacteriaceae producing oxacillinase-48-like carbapenemases, United States, Emerg Infect Dis, 24, 700, 10.3201/eid2404.171377

2020

Katsube, 2016, Pharmacokinetic/pharmacodynamic modeling and simulation of cefiderocol, a parenteral siderophore cephalosporin, for dose adjustment based on renal function, Antimicrob Agents Chemother, 61, e01381

Jacobs, 2018, ARGONAUT-I: activity of cefiderocol (S-649266), a siderophore cephalosporin, against Gram-negative bacteria, including carbapenem-resistant nonfermenters and Enterobacteriaceae with defined extended-spectrum β-lactamases and carbapenemases, Antimicrob Agents Chemother, 63, e01801, 10.1128/AAC.01801-18

Delgado-Valverde, 2020, Activity of cefiderocol against high-risk clones of multidrug-resistant Enterobacterales, Acinetobacter baumannii, Pseudomonas aeruginosa and Stenotrophomonas maltophilia, J Antimicrob Chemother, 75, 1840, 10.1093/jac/dkaa117

2019

Haller, 2019, Extensively drug-resistant Klebsiella pneumoniae ST307 outbreak, North-Eastern Germany, June to October 2019, Euro Surveill, 24, 1900734, 10.2807/1560-7917.ES.2019.24.50.1900734

Politi, 2019, Emergence of NDM-1-producing Klebsiella pneumoniae in Greece: evidence of a widespread clonal outbreak, J Antimicrob Chemother, 74, 2197, 10.1093/jac/dkz176

Savov, 2018, NDM-1 hazard in the Balkan states: evidence of the first outbreak of NDM-1-producing Klebsiella pneumoniae in Bulgaria, Microbiol Drug Resist, 24, 253, 10.1089/mdr.2017.0230

Papadimitriou-Olivgeris, 2019, Reversal of carbapenemase-producing Klebsiella pneumoniae epidemiology from blaKPC- to blaVIM-harbouring isolates in a Greek ICU after introduction of ceftazidime/avibactam, J Antimicrob Chemother, 74, 2051, 10.1093/jac/dkz125

Zak-Doron, 2018, The association between empirical antibiotic treatment and mortality in severe infections caused by carbapenem-resistant Gram-negative bacteria: a prospective study, Clin Infect Dis, 67, 1815

Petty, 2018, Overview of meropenem-vaborbactam and newer antimicrobial agents for the treatment of carbapenem-resistant Enterobacteriaceae, Infect Drug Resist, 11, 1461, 10.2147/IDR.S150447

2019

Bassetti, 2019, Treatment of infections due to MDR Gram-negative bacteria, Front Med, 6, 74, 10.3389/fmed.2019.00074

Ordooei Javan, 2015, A review on colistin nephrotoxicity, Eur J Clin Pharm, 71, 801, 10.1007/s00228-015-1865-4

Oliota, 2019, Nephrotoxicity prevalence in patients treated with polymyxins: a systematic review with meta-analysis of observational studies, Diagn Microbiol Infect Dis, 94, 41, 10.1016/j.diagmicrobio.2018.11.008

Poirel, 2017, Polymyxins: antibacterial activity, susceptibility testing, and resistance mechanisms encoded by plasmids or chromosomes, Clin Microbiol Rev, 30, 557, 10.1128/CMR.00064-16

2016

Nowak, 2017, High incidence of pandrug-resistant Acinetobacter baumannii isolates collected from patients with ventilator-associated pneumonia in Greece, Italy and Spain as part of the MagicBullet Clinical Trial, J Antimicrob Chemother, 72, 3277, 10.1093/jac/dkx322

Falagas, 2017, Activity of cefiderocol (S-649266) against carbapenem-resistant Gram-negative bacteria collected from inpatients in Greek hospitals, J Antimicrob Chemother, 72, 1704, 10.1093/jac/dkx049

Del Barrio-Tofino, 2019, Spanish nationwide survey on Pseudomonas aeruginosa antimicrobial resistance mechanisms and epidemiology, J Antimicrob Chemother, 74, 1825, 10.1093/jac/dkz147

Codjoe, 2017, Carbapenem resistance: a review, Med Sci, 6, 1

Thông tin
Thông tin xuất bản

JAC-Antimicrobial Resistance

Tập 2 Số 3

Thông tin tác giả